FierceBiotechOriginal article
{"a":[{"_":"Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push","$":{"href":"/biotech/sobi-pens-580m-deal-innates-skin-cancer-drug-ahead-phase-3-push","hreflang":"en"}}]}
lacutamabPositive
AI Analysis
Summary
Sobi acquired rights to Innate Pharma's lacutamab, an anti-KIR3DL2 antibody for skin cancer treatment, for $75 million upfront. The deal comes ahead of a Phase 3 trial initiation.
Clinical Trial Data
Phase
3
Importance:7/10
Sentiment:
0.60
acquisitionlicensing dealoncologyskin canceranti-KIR3DL2 antibody
Read the original article
Published by FierceBiotech on August 10, 2026 7:15 AM